TA
TAK.US Takeda Pharmaceutical Co Ltd ADR
- Market cap
- USD 69.1B
- P/E
- 309.1x
- P/B
- 1.49x
- ROE
- 8.2%
- Dividend yield
- 2.86%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.
Is TAK.US undervalued?
Graham numberThe Graham number of Takeda Pharmaceutical Co Ltd ADR cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Takeda Pharmaceutical Co Ltd ADR fundamental analysis
No fundamental analysis for Takeda Pharmaceutical Co Ltd ADR yet.
Takeda Pharmaceutical Co Ltd ADR stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Takeda Pharmaceutical Co Ltd ADR
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, Livtencity, ADZYNMA, Gamm…
Full company profileTakeda Pharmaceutical Co Ltd ADR financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Takeda Pharmaceutical Co Ltd ADR annual financial statements (JPY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.73T | 1.77T | 2.10T | 3.29T | 3.20T | 3.57T | 4.03T | 4.26T | 4.58T | 4.51T | 4.81T |
| Gross Profit | 1.17T | 1.27T | 1.44T | 2.20T | 2.20T | 2.46T | 2.78T | 2.83T | 3.00T | 2.93T | 3.22T |
| Operating Income | 156B | 242B | 205B | 100B | 509B | 461B | 491B | 214B | 343B | 6.22B | 813B |
| EBITDA | 297B | 360B | 464B | 672B | 984B | 1.18T | 1.28T | 1.23T | 1.21T | 727B | 1.43T |
| Net Income | 115B | 187B | 109B | 44.2B | 376B | 230B | 317B | 144B | 108B | -152B | 611B |
| EPS | 73 | 119 | 56 | 14 | 119 | 73 | 101 | 46 | 34 | -48 | 190 |
| Balance Sheet | |||||||||||
| Total Assets | 4.36T | 4.11T | 13.9T | 12.8T | 12.9T | 13.2T | 14.0T | 15.1T | 14.2T | 15.5T | 15.3T |
| Total Liabilities | 2.41T | 2.09T | 8.71T | 8.09T | 7.74T | 7.49T | 7.60T | 7.83T | 7.31T | 7.71T | 7.85T |
| Shareholders' Equity | 1.89T | 2.00T | 5.16T | 4.72T | 5.17T | 5.68T | 6.35T | 7.27T | 6.94T | 7.81T | 7.42T |
| Cash & Short-term Investments | 376B | 375B | 725B | 653B | 1.00T | 875B | 554B | 473B | 406B | 598B | 454B |
| Total Debt | 1.14T | 986B | 5.75T | 5.09T | 4.64T | 4.35T | 4.38T | 4.84T | 4.52T | 4.90T | 4.58T |
| Cash Flow | |||||||||||
| Operating Cash Flow | 261B | 378B | 328B | 670B | 1.01T | 1.12T | 977B | 716B | 1.06T | 1.04T | 770B |
| Capital Expenditure | 112B | 128B | 134B | 218B | 236B | 186B | 634B | 481B | 380B | 415B | 197B |
| Free Cash Flow | 149B | 250B | 194B | 452B | 774B | 937B | 343B | 236B | 678B | 627B | 573B |
| Ratios | |||||||||||
| ROE | 6.1% | 9.4% | 2.1% | 0.9% | 7.3% | 4.0% | 5.0% | 2.0% | 1.6% | -2.0% | 8.2% |
| ROA | 2.6% | 4.6% | 0.8% | 0.3% | 2.9% | 1.7% | 2.3% | 1.0% | 0.8% | -1.0% | 4.0% |
| Net Profit Margin | 6.6% | 10.6% | 5.2% | 1.3% | 11.8% | 6.4% | 7.9% | 3.4% | 2.4% | -3.4% | 12.7% |
| Debt to Equity | 0.60x | 0.49x | 1.11x | 1.08x | 0.90x | 0.76x | 0.69x | 0.67x | 0.65x | 0.63x | 0.62x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Takeda Pharmaceutical Co Ltd ADR dividends
- Dividend yield
- 2.86%
- Forward dividend
- 0.62 USD
- Payout ratio
- -
- Ex-dividend date
- Mar 31, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | JPY 312B | 99 | - |
| 2025 | JPY 302B | 94 | 280.3% |
| 2024 | JPY 287B | 91 | 199.3% |
| 2023 | JPY 279B | 89 | 88.1% |
| 2022 | JPY 284B | 90 | 123.3% |
| 2021 | JPY 283B | 90 | 75.4% |
| 2020 | JPY 283B | 90 | 638.7% |
| 2019 | JPY 143B | 74 | 131.0% |
| 2018 | JPY 142B | 90 | 75.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Takeda Pharmaceutical Co Ltd ADR
- Insiders 0.11%
- Institutions 3.88%
- Public & others 96.01%
- Shares outstanding 3.19B
- Free float 3.19B
Top funds holding TAK.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| American Funds American Mutual A | 18.2M | 0.57% | 0.00% | Sep 2026 |
| American Funds Capital Inc Bldr A | 7.34M | 0.23% | 0.00% | Sep 2026 |
| First Trust Value Line® Dividend ETF | 1.62M | 0.05% | 0.00% | Oct 2026 |
| VanEck Pharmaceutical ETF | 1.51M | 0.05% | +0.54% | Oct 2026 |
| Steward Values Enhanced International I | 712K | 0.02% | 0.00% | Sep 2026 |
| Avantis International Equity ETF | 565K | 0.02% | 0.00% | Oct 2026 |
| Amplify CWP International Enh Div IncETF | 520K | 0.02% | +108.00% | Oct 2026 |
| Mercer Non-US Core Equity Y3 | 514K | 0.02% | -9.40% | Sep 2026 |
| Catalyst/MAP Global Equity A | 169K | 0.01% | 0.00% | Jun 2026 |
| ActivePassive International Equity ETF | 152K | 0.00% | 0.00% | Oct 2026 |
| VALMXVL B1 | 148K | 0.00% | 0.00% | Sep 2026 |
| Vanguard FTSE All-Wld ex-US ETF | 123K | 0.00% | 0.00% | Sep 2026 |
| Carillon Chartwell Real Income I | 120K | 0.00% | -25.00% | Sep 2026 |
| American Funds IS® Capital Inc Builder®2 | 104K | 0.00% | 0.00% | Sep 2026 |
| iShares Dynamic Equity Active ETF | 89.3K | 0.00% | +0.42% | Oct 2026 |
| Capital Group CIB LUX Z | 84.4K | 0.00% | 0.00% | Jul 2026 |
| Middlefield Healthcare Dividend ETF | 79.1K | 0.00% | -13.46% | Oct 2026 |
| Strategic Advisers International | 66.4K | 0.00% | 0.00% | Sep 2026 |
| Adasina Social Justice All Cp Glbl ETF | 59.6K | 0.00% | 0.00% | Oct 2026 |
| Middlefield Healthcare Dividend F | 57.3K | 0.00% | -27.10% | Oct 2026 |
Top institutions holding TAK.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Capital Research Global Investors | 27.0M | 0.84% | +39.67% | Sep 2026 |
| FMR Inc | 9.60M | 0.30% | +34.87% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 6.99M | 0.22% | +8.12% | Jun 2026 |
| Adage Capital Partners Gp LLC | 6.05M | 0.19% | -5.82% | Jun 2026 |
| The Goldman Sachs Group Inc | 5.13M | 0.16% | -8.79% | Jun 2026 |
| Brandes Investment Partners & Co | 4.54M | 0.14% | +2.45% | Jun 2026 |
| Arrowstreet Capital Limited Partnership | 3.73M | 0.12% | +19.79% | Jun 2026 |
| BlackRock Inc | 3.69M | 0.12% | +16.11% | Jun 2026 |
| Renaissance Technologies Corp | 2.29M | 0.07% | -10.72% | Sep 2026 |
| Qube Research & Technologies | 2.21M | 0.07% | 0.00% | Jun 2026 |
| First Trust Advisors L.P. | 2.11M | 0.07% | +7.30% | Jun 2026 |
| D. E. Shaw & Co LP | 2.05M | 0.06% | -21.25% | Jun 2026 |
| Managed Asset Portfolios, LLC | 1.82M | 0.06% | +1.42% | Jun 2026 |
| Northern Trust Corp | 1.74M | 0.05% | -11.26% | Jun 2026 |
| Van Eck Associates Corporation | 1.67M | 0.05% | -25.93% | Jun 2026 |
| AQR Capital Management LLC | 1.53M | 0.05% | +70.58% | Jun 2026 |
| Quantinno Capital Management LP | 1.40M | 0.04% | +8.79% | Jun 2026 |
| Wells Fargo & Co | 1.15M | 0.04% | +1.30% | Jun 2026 |
| Millennium Management LLC | 1.05M | 0.03% | 0.00% | Jun 2026 |
| UBS Group AG | 911K | 0.03% | -66.74% | Jun 2026 |
Takeda Pharmaceutical Co Ltd ADR company profile
- Company name
- Takeda Pharmaceutical Co Ltd ADR
- Ticker
- TAK.US
- Exchange
- USA Stocks
- Listed since
- Oct 27, 2008
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 47,029
- Fiscal year end
- March
- Address
- 1-1, Nihonbashi-Honcho 2-chome, Chuo, Japan, 103-8668
- Phone
- 81 3 3278 2111
- Website
- takeda.com
About Takeda Pharmaceutical Co Ltd ADR
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, Livtencity, ADZYNMA, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Flexbumin, Adcetris, Leuplin/Enantone, Ninlaro, Iclusig, FRUZAQLA, Alunbrig, vyvanse/elvanse, Trintellix, and QDENGA brands. It has licensing and collaboration for the development and commercialization of products with Arrowhead Pharmaceuticals, Cour Pharmaceuticals, Engitix, Halozyme, Mirum Pharmaceuticals, Ucsd/Fortis Advisors, Zedira/Dr. Falk Pharma, Ac Immune, Acurastem, Anima Biotech, Biomarin, Denali Therapeutics, Luxna Biotech, Neurocrine Biosciences, Peptidream, Abbvie, Adimab, Ascentage Pharma, Crescendo Biologics, Exelixis, F-Star, Gsk, Heidelberg Pharma, Innovent Biologics, Keros Therapeutics, Kumquat Biosciences, Protagonist Therapeutics, Halozyme, Kamada, Johnson & Johnson/Momenta Pharmaceuticals, Previpharma, Novavax, Bridgene Biosciences, Charles River Laboratories, Iambic Therapeutics, Ipsen, Km Biologics, Massachusetts Institute Of Technology, and Nabla Bio. The company operates in Japan, the United States. Europe, Canada, Latin America, China, Asia, Russia/Commonwealth of Independent States, the Middle East, Oceania, and Africa. The company was founded in 1781 and is headquartered in Chuo, Japan.
Takeda Pharmaceutical Co Ltd ADR management
10- Mr. Milano FurutaCFO & Director · born 1978
- Dr. Andrew S. Plump M.D., Ph.D.President of Research & Development and Representative Director · born 1965
- Ms. Julie KimCEO, President & Director · born 1970
- Dr. Seigo IzumoChair of Management Board
- Mr. Haruhiko HirateMember of Management Board · born 1957
- Mr. Salvatore Alesci M.D., Ph.D.Member of Management Board and Head of R&D Global Science & Biomedical Policy · born 1975
- Michael FoxChief Operating Officer
- Norimasa TakedaChief Accounting Officer & Corporate Controller
- Mr. Iwaaki TaniguchiSenior Vice President of Corporate Finance & Controlling Department
- Mr. Gabriele RicciChief Data & Technology Officer · born 1978